Read this company snapshot
Daily valuation snapshot
BioAge Labs, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $6.34
- Market capitalization (USD)
- $290,986,403.06
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.78
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BIOA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BIOA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing BIOA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $6.34 |
| Market capitalization (USD) | $290,986,403.06 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.78 |
No matching rows. Clear the filter to see all records.
Read BIOA's valuation metrics
Company size
BioAge Labs, Inc. Common Stock's recorded market capitalization is $290,986,403.06. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
BIOA's recorded price-to-book ratio is 0.78. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research BioAge Labs, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about BIOA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow BIOA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.